Instrument Inactif

Communiqués Arbutus Biopharma Corp Nasdaq

Actions

CA87911B2093

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

06/06	Arbutus Biopharma annonce que la thérapie Imdusiran Plus VTP-300 abaisse les niveaux d'HBsAg dans l'étude	MT
06/06	Arbutus Biopharma Corporation annonce de nouvelles données préliminaires de fin de traitement de l'essai clinique de phase 2A	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Inherency Remains High Bar To Meet	26/06	AQ
Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	07/06	AQ
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	06/06	GL
Arbutus Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	06/06	AQ
Arbutus Biopharma : Corporate Presentation - June 2024	05/06	PU
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	05/06	GL
Arbutus to Participate in Jefferies Global Healthcare Conference	29/05	GL
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05	AQ
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05	GL
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	20/05	AQ
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	17/05	BU
Arbutus to Participate in Two Upcoming Investor Conferences	07/05	GL
Arbutus Biopharma : Corporate Presentation - May 2024	02/05	PU
Arbutus: Q1 Earnings Snapshot	02/05	AQ
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update	02/05	GL
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024	02/05	GL
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18/04	GL
Arbutus Biopharma : Corporate Presentation - April 2024	15/04	PU
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04/04	GL
Arbutus to Participate in Two Upcoming Investor Conferences	08/03	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Arbutus Biopharma Corp Nasdaq

Actions

CA87911B2093

Communiqués

Filtres